Bioventus (BVS) Proxy filing summary

Executive summary

• Achieved or exceeded financial guidance for the third consecutive year, reflecting disciplined operational execution and improved commercial performance.

• Advanced growth drivers with pilot launches in Peripheral Nerve Stimulation and Platelet Rich Plasma products, receiving positive early market feedback.

• Focus for 2026 is on accelerating top-line growth, expanding profitability, and reinvesting in innovation to enhance shareholder returns.

• Annual Meeting scheduled for June 3, 2026, to be held virtually, with all shareholders encouraged to vote.

Voting matters and shareholder proposals

• Shareholders will vote on the election of twelve directors to serve until the 2027 Annual Meeting.

• Ratification of Grant Thornton LLP as the independent registered public accounting firm for fiscal year 2026.

• Board recommends voting FOR all director nominees and FOR the auditor ratification.

• Shareholders may submit proposals for the 2027 Annual Meeting by December 23, 2026.

Board of directors and corporate governance

• Board consists of twelve directors with diverse backgrounds in healthcare, finance, and governance.

• Board structure transitioned from classified to annual elections starting with this meeting.

• Eleven of twelve directors are independent under Nasdaq rules.

• Four standing committees: Audit and Risk, Compensation, Compliance, Ethics and Culture, and Nominating and Corporate Governance.

• Board leadership roles are separated between Chairperson and CEO.